I think it's a matter of hitting the right level of funding. As we've stated, Pharmac has done a good job with what the agreement is, but it's a matter of funding it at the right level. I'm not sure whether Matthew touched on this, but Pharmac received a very large increase in funding last year, a record new investment in funding. I remember that was based on the business cases built around innovative medicines, such as the melanoma medicines, the hepatitis C medicines. These are medicines that are curing people of disease in some cases, and they are reducing the bills upstream, which is a point I touched on.
I think it's a matter of having a good balance among things, and it shouldn't be done on a cost containment model. It should be based on the best return on investment, looking beyond the medical budget to the impact it will have more broadly on society and the health care system itself. It is a way of looking at as an ambulance at the top of the cliff versus an ambulance at the bottom. The ambulance at the bottom will often cost more money.